Parkinson's disease (PD) is the second most common neurodegenerative disorder, primarily characterized by motor dysfunction.

Study explains long-standing question of why Huntington’s disease symptoms typically do not appear until midlife even though ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

Teams within the Scientific Tracks will join the ASAP CRN, an international, multidisciplinary, and multi-institutional network of collaborating investigators working to address high-priority research ...

While hearing loss has been associated with cognitive decline and considered a risk factor for dementia, this study, ...

There may be a link between hearing impairment and an increased risk of developing Parkinson's according to new research. This is one of the first studies to examine whether sensory impairments, such ...

A new study has identified a potential link between hearing impairment and an increased risk of developing Parkinson’s disease.

Treatment with an oral allosteric modulator was nonsuperior to placebo at 6 weeks in adults with Parkinson’s disease whose ...

Berlin, Germany, and Research Triangle Park, N.C., USA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Not intended for UK MediaEnrollment ongoing in the ...

The unique plasma assets serve as the foundation of the Chronos-PD program, driving advanced research at Grifols subsidiary Alkahest, which is leading the initiative given its specialization in the ...

Sleep disturbances encompass a broad range of disorders, such as insomnia, restless legs syndrome, parasomnias, sleep-disordered breathing, daytime ...

Regeneron Pharmaceuticals (NASDAQ:REGN) said it currently expects that its financial results for the fourth quarter 2024 will ...